肝细胞癌根治性治疗后的辅助治疗的现状和前景

StephenW

Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects
Xiao-Dong Zhu  1 , Kang-Shuai Li  1 , Hui-Chuan Sun  1
Affiliations
Affiliation

    1
    Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

    PMID: 32884990 PMCID: PMC7452398 DOI: 10.1016/j.gendis.2020.02.002

Abstract

Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma (HCC) is as high as 70%. However, there are no widely accepted adjuvant therapies; therefore, no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Association for the Study of the Liver. All the registered trials failed to find any treatment to prolong recurrence-free survival, which is the primary outcome in most studies, including sorafenib. Some investigator-initiated studies revealed that anti-hepatitis B virus agents, interferon-α, transcatheter chemoembolization, chemokine-induced killer cells, and other treatments prolonged patient recurrence-free survival or overall survival after curative therapies. In this review, we summarize the current status of adjuvant treatments for HCC and explain the challenges associated with designing a clinical trial for adjuvant therapy. Promising new treatments being used as adjuvant therapy, especially anti-PD-1 antibodies, are also discussed.

Keywords: Adjuvant therapy; Anti-PD-1 antibody; CIK, chemokine-induced killer cells; CR, complete response; Clinical trial; HCC, hepatocellular carcinoma; Hepatocellular carcinoma; ICI, immune checkpoint inhibitor; Molecular targeted therapy; ORR, objective response rate; OS, overall survival; PD-1, program death-1; PD-L1, program death-1 ligand; PR, partial response; RCT, randomized clinical trial; RECIST, Response Evaluation Criteria in Solid Tumors; RFS, recurrence-free survival; Recurrence-free survival; TACE, transcatheter chemoembolization; TKI, tyrosine kinase inhibitor.

© 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.
Conflict of interest stateme

StephenW

肝细胞癌根治性治疗后的辅助治疗的现状和前景
朱晓东1，李康帅1，孙惠传1
隶属关系
联系

    1个
    复旦大学附属肝癌研究所和中山医院肝外科，上海200032

    PMID：32884990 PMCID：PMC7452398 DOI：10.1016 / j.gendis.2020.02.002

抽象

手术切除或消融肝细胞癌（HCC）后的肿瘤复发率高达70％。但是，目前还没有被广泛接受的辅助疗法。因此，美国肝病研究协会或欧洲肝病研究协会的指南均未建议任何治疗方法。所有已注册的试验均未找到延长无复发生存期的任何治疗方法，这是包括索拉非尼在内的大多数研究的主要结果。一些研究者发起的研究表明，抗乙型肝炎病毒药物，干扰素-α，经导管化学栓塞，趋化因子诱导的杀伤细胞以及其他治疗方法可延长患者的无复发生存期或治愈后的总体生存期。在这篇综述中，我们总结了肝癌辅助治疗的现状，并解释了与设计辅助治疗临床试验相关的挑战。还讨论了有望用作辅助疗法的新疗法，特别是抗PD-1抗体。

关键词：辅助治疗抗PD-1抗体; CIK，趋化因子诱导的杀伤细胞； CR，完整的回应；临床试验; HCC，肝细胞癌；肝细胞癌； ICI，免疫检查点抑制剂；分子靶向治疗； ORR，客观回应率； OS，整体生存率； PD-1，程序死亡1； PD-L1，程序性死亡1配体； PR，部分反应； RCT，随机临床试验； RECIST，实体瘤反应评估标准； RFS，无复发生存；无复发生存； TACE，经导管化学栓塞； TKI，酪氨酸激酶抑制剂。

©2020重庆医科大学。 Elsevier B.V.的制作和托管

StephenW

https://www.sciencedirect.com/sc ... 20300325?via%3Dihub